{"id":29286,"date":"2022-04-27T10:00:22","date_gmt":"2022-04-27T08:00:22","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=29286"},"modified":"2022-05-30T12:05:48","modified_gmt":"2022-05-30T10:05:48","slug":"glucagon-like-peptide-1-analoga-erhoehtes-risiko-fuer-gallenwegserkrankungen-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2022\/glucagon-like-peptide-1-analoga-erhoehtes-risiko-fuer-gallenwegserkrankungen-cme","title":{"rendered":"Glucagon-like peptide-1-Analoga: erh\u00f6htes Risiko f\u00fcr Gallenwegserkrankungen [CME]"},"content":{"rendered":"<p>Analoga des Glucagon-like-peptide-1 (GLP-1-A, Inkretinmimetika) stimulieren Glukose-abh\u00e4ngig die Insulin-, inhibieren die Glukagon-Inkretion und senken den HbA1c-Wert je nach Wirkstoff, Dosis und Pharmakokinetik um 0,55 bis 1,7%-Punkte . GLP-1-A z\u00e4hlen auch zu den Antidiabetika, f\u00fcr die eine Reduktion kardiovaskul\u00e4rer Ereignisse nachgewiesen ist . Daher werden GLP-1-A inzwischen in den Leitlinien f\u00fcr Typ-2-Diabetiker mit manifesten kardiovaskul\u00e4ren Vorerkrankungen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Analoga des Glucagon-like-peptide-1 (GLP-1-A, Inkretinmimetika) stimulieren Glukose-abh\u00e4ngig die Insulin-, inhibieren die Glukagon-Inkretion und senken den HbA1c-Wert je nach Wirkstoff, Dosis und Pharmakokinetik um 0,55 bis 1,7%-Punkte . GLP-1-A z\u00e4hlen auch zu den Antidiabetika, f\u00fcr die eine Reduktion kardiovaskul\u00e4rer Ereignisse nachgewiesen ist . Daher werden GLP-1-A inzwischen in den Leitlinien f\u00fcr Typ-2-Diabetiker mit manifesten kardiovaskul\u00e4ren Vorerkrankungen [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1159,3896,5671,155,3135,2822,5504,5670,1309,2823,4489,2598,5479,1158],"class_list":["post-29286","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-adipositas","tag-cholelithiasis","tag-cholezystitis","tag-diabetes-mellitus-typ-2","tag-dulaglutid","tag-exenatid","tag-glucagon-like-peptide-receptor","tag-glucagon-like-peptide-1-analoga","tag-inkretinmimetika","tag-liraglutid","tag-lixisenatid","tag-pankreatitis","tag-semaglutid","tag-uebergewicht"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/29286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=29286"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/29286\/revisions"}],"predecessor-version":[{"id":29287,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/29286\/revisions\/29287"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=29286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=29286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=29286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}